Topline Phase III Efpeglenatide Data Raise Hopes For Hanmi’s Obesity Contender

Korea Approval Filing Eyed This Year

 
• By Jung Won Shin
  
Obesity
Hanmi Expects Efpeglenatide To Show Expandability In Metabolic Diseases (Shutterstock)

More from Clinical Trials

More from R&D